Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Rationale: Clinical variables associated with shortened survival in patients with advanced-stage cystic fibrosis (CF) are not included in the lung allocation score (LAS). Objectives: To identify variables associated with wait-list and post-transplant mortality for CF lung transplant candidates using a novel database and to analyze the impact of including new CF-specific variables in the LAS system. Methods: A deterministic matching algorithm identified patients from the Scientific Registry of Transplant Recipients and the Cystic Fibrosis Foundation Patient Registry. LAS wait-list and post-transplant survival models were recalculated using CF-specific variables. This multicenter, retrospective, population-based study of all lung transplant wait-list candidates aged 12 years or older from January 1, 2011, to December 31, 2014, included 9,043 patients on the lung transplant waiting list and 6,110 lung transplant recipients between 2011 and 2014, comprising 1,020 and 677 with CF, respectively. Measurements and Main Results: Measured outcomes were changes in LAS and lung allocation rank. For CF candidates, any Burkholderia sp. (hazard ratio [HR], 2.8; 95% confidence interval [CI], 1.2–6.6), 29–42 days hospitalized (HR 2.8; CI 1.3–5.9), massive hemoptysis (HR 2.1; CI 1.1–3.9), and relative drop in FEV1 ≥30% over 12 months (HR 1.7; CI 1.0–2.8) increased wait-list mortality risk; pulmonary exacerbation time 15–28 days (1.8; 1.1–2.9) increased post-transplant mortality risk. A relative drop in FEV1 ≥10% in chronic obstructive pulmonary disease (COPD) candidates was associated with increased wait-list mortality risk (HR 2.6; CI 1.2–5.4). Variability in LAS score and rank increased in patients with CF. Priority for transplant increased for COPD candidates. Access did not change for other diagnosis groups. Conclusions: Adding CF-specific variables improved discrimination among wait-listed CF candidates and benefited COPD candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Independent of FEV1, the following factors have been associated with increasing risk of disease progression or death: frequent or severe exacerbations, massive hemoptysis requiring bronchial artery embolization, pneumothorax, malnutrition, low six-minute walk distance, and younger age upon development of advanced disease.(247, 252–260)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [247]
In the citing paper
“Additional risk factors for mortality in those with severely compromised lung function include FEV1< 25% predicted, rapid decline in FEV1, PaCO2 > 50mmHg, impaired functional status, and pulmonary hypertension. (244, 246–251)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [247]
In the citing paper
“Infection or colonization with multi-drug resistant organisms including Burkholderia cepacia complex, Pseudomonas aeruginosa, and nontuberculous mycobacteria (M. abscessus in particular) have been shown to increase the rate of lung function decline or death without transplant in advanced CF.(245, 247, 254, 258, 262)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [247]
Citations
Cites
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015 · cited 1×
“Moreover, FEV1 is known to be a risk factor for death among non-CF lung transplant patient populations (12, 13).”
BackgroundDyspnea Is a Better Predictor of 5-Year Survival Than Airway Obstruction in Patients With COPD
Nishimura, K., Izumi, T., Tsukino, M., & Oga, T. (2002) · Chest · doi:10.1378/chest.121.5.1434 · Cited by 996
Prediction of mortality in patients with cystic fibrosis
Kerem, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261804 · Cited by 993
Prognosis in Chronic Obstructive Pulmonary Disease 1– 3
Anthonisen, N. R., Wright, E. C., Hodgkin, J. E., & IPPB Trial Group (1986) · American Review of Respiratory Disease · doi:10.1164/arrd.1986.133.1.14 · Cited by 777
Development of the New Lung Allocation System in the United States
Egan, T. M., Murray, S., Bustami, R. T., Shearon, T. H., McCullough, K. P., Edwards, L. B., Coke, M. A., Garrity, E. R., Sweet, S. C., Heiney, D. A., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01276.x · Cited by 767 · cited 3×
“Conclusions The LAS was developed with the goal of allocating organs to candidates at the greatest risk of death and most likely to experience a survival benefit with transplant (3).”
BackgroundMethodInfluentialPredictive 5-year survivorship model of cystic fibrosis
Liou, T. G., Adler, F. R., FitzSimmons, S. C., Cahill, B. C., Hibbs, J. R., & Marshall, B. C. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.345 · Cited by 749
Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation
Sanders, D. B., Bittner, R. C. L., Rosenfeld, M., Hoffman, L. R., Redding, G. J., & Goss, C. H. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1421oc · Cited by 519
Knapp, E. A., Fink, A. K., Goss, C. H., Sewall, A., Ostrenga, J., Dowd, C., Elbert, A., Petren, K. M., & Marshall, B. C. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201511-781oc · Cited by 346 · cited 1×
“The CFFPR is estimated to include approximately 81–84% of people with CF in the United States and included 29,497 individuals in 2016 (1, 9).”
BackgroundSelf-citationLeppke, S., Leighton, T., Zaun, D., Chen, S.-C., Skeans, M., Israni, A. K., Snyder, J. J., & Kasiske, B. L. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.01.002 · Cited by 307 · cited 1×
“We created a database that matched patients found in both the SRTR and CFFPR databases (8, 10).”
MethodSelf-citationDeveloping cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
Mayer-Hamblett, N., Rosenfeld, M., Emerson, J., Goss, C. H., & Aitken, M. L. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200202-087oc · Cited by 269
Research works printed but not linked: 3
- Dasenbrook, 2017, Addition of FEV1 drop to LAS may improve access of CF patients to transplant: analysis of the SRTR and US CF Foundation patient registries [abstract], Am J Transplant, 17, 262
- Dasenbrook, 2016, Description of a novel database: merging the US CF Patient Registry with the Scientific Registry of Transplant Recipients [abstract], Pediatr Pulmonol, 51, 377
- Traver, 1979, Predictors of mortality in chronic obstructive pulmonary disease: a 15-year follow-up study, Am Rev Respir Dis, 119, 895
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
“…mycobacteria ( M. abscessus in particular) have been shown to increase the rate of lung function decline or death without transplant in advanced CF. 245,247,254,258,262 Implications of B. cenoce-pacia, M. abscessus , or L. prolificans are described above (infectious disease risk factors).”
BackgroundSelf-citationESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis
Wilschanski, M. A., Munck, À., Carrión‐Jaramillo, E., Cipolli, M., Collins, S., Colombo, C., Declercq, D., Hatziagorou, E., Hulst, J. M., Kalnins, D., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.12.017 · Cited by 151
Burgel, P., Southern, K. W., Addy, C., Battezzati, A., Berry, C. A., Bouchara, J., Brokaar, E. J., Brown, A. W., Azevedo, P., Durieu, I., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.01.005 · Cited by 118
“…the subject of consensus documents [193] and practical guidelines [194], recognizing the specific needs of people with CF. Determining the optimal timing for lung transplantation remains difficult and may differ between countries based on health system and organ allocation differences [195,196].”
BackgroundAcute Pulmonary Exacerbations in Cystic Fibrosis
Goss, C. H. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1697975 · Cited by 109
Organ Transplantation for Cystic Fibrosis
Morrell, M. R., Kiel, S., & Pilewski, J. M. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399554 · Cited by 32
Stephenson, A. L., Ramos, K. J., Sykes, J., Ma, X., Stanojevic, S., Quon, B. S., Marshall, B. C., Petren, K., Ostrenga, J. S., Fink, A. K., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.12.001 · Cited by 30
Self-citationKolaitis, N. A., Chen, H., Calabrese, D. R., Kumar, K., Obata, J., Bach, C., Golden, J. A., Simon, M. A. M., Kukreja, J., Hays, S. R., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0217oc · Cited by 23
Diagnosis and Management of Cystic Fibrosis Exacerbations
Milinic, T., McElvaney, O. J., & Goss, C. H. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1760250 · Cited by 26
Lung transplantation: a review of the optimal strategies for referral and patient selection
Mitchell, A. B., & Glanville, A. R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619880078 · Cited by 22
Bonner, S. N., Thumma, J. R., Valbuena, V. S. M., Stewart, J. W., Combs, M. P., Lyu, D. M., Chang, A. C., Lin, J., & Wakeam, E. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.02.1496 · Cited by 16
Lung Transplantation in a New Era in the Field of Cystic Fibrosis
Huang, W., Smith, A., Korotun, M., Iacono, A. T., & Wang, J. (2023) · Life · doi:10.3390/life13071600 · Cited by 21
“While data are limited, and are not yet validated in an era where use of modulator therapy is more widespread, there is some literature to suggest that use of parameters specific to mortality in CF would increase the predictive value of the LAS for this demographic [30].”
BackgroundCell-Free DNA Maps Tissue Injury and Correlates with Disease Severity in Lung Transplant Candidates
Balasubramanian, S., Richert, M. E., Kong, H., Fu, S., Jang, M. K., Andargie, T. E., Keller, M. B., Alnababteh, M. H., Park, W., Apalara, Z., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202306-1064oc · Cited by 15
Coriati, A., Sykes, J. R., Lemonnier, L., Ma, X., Stanojevic, S., Dehillotte, C., Carlier, N., Stephenson, A. L., & Burgel, P. (2021) · European Respiratory Journal · doi:10.1183/13993003.00014-2021 · Cited by 12
Mitchell, A. B., & Glanville, A. R. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1728797 · Cited by 13
Hoffman, T. W., Hemke, A. C., Zanen, P., Luijk, B., Hoek, R. A. S., Verschuuren, E. A. M., & van Kessel, D. A. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001205 · Cited by 13
The Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 13
Ramos, K. J., Wai, T. H., Stephenson, A. L., Sykes, J. R., Stanojevic, S., Rodriguez, P. J., Bansal, A., Mayer-Hamblett, N., Goss, C. H., & Kapnadak, S. G. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.05.021 · Cited by 9
Update on Lung Transplantation for Cystic Fibrosis
Pilewski, J. M. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.07.002 · Cited by 10
Pediatric lung transplantation for childhood interstitial lung disease: Indications and outcome
Schneider, H., Ius, F., Müller, C., Salman, J., Schütz, K., Köditz, H., Nickel, K., Hansen, G., Bobylev, D., Schwerk, N., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.04.001 · Cited by 6
Bayomy, O. F., Ramos, K. J., Wai, T. H., Kapnadak, S. G., Morrell, E. D., Nomitch, J. T., Pollack, L. R., Lease, E. D., Aitken, M. L., Stephenson, A. L., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202202-110oc · Cited by 6
Call for Changes in Lung Allocation to Reduce Transplant Wait-List Mortality for Cystic Fibrosis
Nolley, E. P., & Pilewski, J. M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201907-1385ed · Cited by 7
Lehr, C. J., & Pilewski, J. M. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000975 · Cited by 4
“Although the number of individuals with CF needing transplant will decline for the foreseeable future, numbers will increase as individuals survive longer and eventually develop ALD.”
BackgroundInfluentialSelf-citationGambazza, S., Carta, F., Ambrogi, F., Bassotti, G., Brivio, A., Russo, M. C., & Colombo, C. (2022) · Disability and Rehabilitation · doi:10.1080/09638288.2022.2099588 · Cited by 3
Lung Transplantation: Selection of Candidates
Thomas, C., Williams, M., & Shlobin, O. A. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2304197 · Cited by 2
Schold, J. D., Hoffman, J. R. H., Mohan, S., Gray, A., Lopez, R., Arrigain, S., Brosi, D. N., LaVanchy, R., Husain, S., Yu, M. E., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.04.004 · Cited by 2
Cystic fibrosis year in review 2019: Section 2 pulmonary disease and infections
Savant, A. P., & McColley, S. A. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25091 · Cited by 1
“Data from the scientific registry of transplantation recipients, the organ procurement, and transplantation network and the CFFPR were analyzed.(61) Variables that increased risk”
MethodImproving lung transplant outcomes in France: the high emergency lung transplantation programme
Bayomy, O. F., Ramos, K. J., & Goss, C. H. (2022) · European Respiratory Journal · doi:10.1183/13993003.02209-2021 · Cited by 2
Cromwell, E. A., Ahn, Y. S., Johnson, P. J., Ramos, K. J., Freeman, A. J., Faro, A., & Snyder, J. J. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.09.015 · Cited by 1
“For the purpose of evaluating the matched population with a history of lung transplant, we restricted those reported in 2005 or later years to account for the introduction of the lung allocation score [16].”
Self-citationThe 49th parallel: Does geographic position affect longevity of patients with cystic fibrosis?
Hadjiliadis, D., Valapour, M., Chaparro, C., Cypel, M., & Cooper, J. D. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.01.048 · Cited by 1
“The LAS system does not allocate donor lungs based on likelihood of long-term survival and does not account for key variables that are known predictors of waitlist mortality in the population of persons living with CF—both of which result in underestimation of survival benefit in CF population.(10)”
BackgroundSelf-citationGoldberg, H. J. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202209-1816ed · Cited by 1
A significant shift to the right
Hayanga, J. W. A., Tiko-Okoye, C. S., & Hayanga, H. K. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.06.020
Lung Transplantation for Cystic Fibrosis
Pilewski, J. M. (2020) · Respiratory medicine · doi:10.1007/978-3-030-42382-7_12
Lung Allocation Score Exceptions in Persons with Cystic Fibrosis Undergoing Lung Transplant
Bayomy, O. F., Bradford, M. C., Milinic, T., Kapnadak, S. G., Morrell, E. D., Lease, E. D., Goss, C. H., & Ramos, K. J. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202306-509oc
Manajemen Fisioterapi pada Asma : Laporan Kasus
Irianto, I., Putri, D. S., Kamrawati, K., & Syahar, A. (2024) · Jurnal Fisioterapi dan Rehabilitasi · doi:10.33660/jfrwhs.v8i2.323
Process and validity of linking cystic fibrosis patient registry with national Medicaid databases
Esther, C. R., Rua, M., Chen, H., Cromwell, E. A., & Setoguchi, S. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.10.012
Entwicklung von pulmonalarteriellem Blutdruck bei terminalen Lungenerkrankungen
Grauvogl, N. A. (2023) · doi:10.5282/edoc.32830 · Cited by 1
Metadata
- Authors
- Lehr, C. J., Skeans, M., Dasenbrook, E., Fink, A., Fernandez, G., Faro, A., & Valapour, M.
- Affiliations
- Cleveland Clinic (US)
- Hennepin Healthcare Research Institute (US)
- Cystic Fibrosis Foundation (US)
- Corresponding author
- Valapour, Maryam
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10
- Volume
- 200
- Issue
- 8
- Pages
- 1013-1021
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2950878989
- Semantic Scholar
- 16938c35a47167c479d7337b7a5902a6fecaadd0
- Cited by
- 35
- References
- 27
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 8 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 4
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cystic Fibrosis Foundation
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
- Keywords
- lung allocation score, cystic fibrosis, chronic obstructive pulmonary disease, lung transplantation, post-transplant mortality, Burkholderia, pulmonary exacerbations, FEV1 decline, transplant prioritization, clinical risk factors
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Algorithms, Child, Cystic Fibrosis, Female, Humans, Male, Middle Aged, Tissue and Organ Procurement, Retrospective Studies, Severity of Illness Index, Waiting Lists, Reproducibility of Results, Proportional Hazards Models, Lung Transplantation, Practice Guidelines as Topic, Patient Selection, Pulmonary Disease, Chronic Obstructive, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.